Janssen Research & Development
3210 Merryfield Row
San Diego
California
92121
United States
Tel: 858-450-2000
About Janssen Research & Development
At Janssen Research & Development, LLC, we are united and energized by one mission – to discover and develop innovative medicines that ease patients' suffering, and solve the most important unmet medical needs of our time.As one of the Janssen Pharmaceutical Companies, our strategy is to identify the biggest unmet medical needs and match them with the best science, internal or external, to find solutions for patients worldwide. We leverage our world-class discovery and development expertise, and operational excellence, to bring innovative, effective treatments in five therapeutic areas:
• cardiovascular and metabolism, • immunology, • infectious diseases and vaccines, • neuroscience, and • oncology.
We think of the world as our laboratory and we look for innovation wherever it exists. This drives our relentless search for the best science, and our pursuit of collaborations and partnerships.
We believe there are no limits to what science can do. And we never lose sight of those who rely most on our discoveries.
Website: http://www.janssenrnd.com/our-company
Janssen Labs is part of Johnson & Johnson’s external research and development engine and provides a capital-efficient, resource-rich environment where independent emerging companies can progress their research. The 30,000 square foot flagship facility opened in early 2012 in San Diego at Janssen’s West Coast Research Center and currently hosts 30 emerging life science companies. Janssen Labs offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Janssen Labs is an open innovation model, and the agreement for space does not grant Janssen any stake in the companies, nor will the companies have a guaranteed future affiliation with Janssen; but the models is designed to initiate a dialogue early and foster long term relationships with innovators in healthcare.
http://www.janssenlabs.com/about/overview
130 articles about Janssen Research & Development
-
Janssen Research & Development To Showcase Data From Five Compounds Including Daratumumab And IMBRUVICA At The 2015 ASCO Annual Meeting
5/14/2015
-
Janssen Research & Development Release: New Study Published In JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time To Relapse In Patients With Schizophrenia
3/30/2015
-
JDRF Supports Janssen Research & Developments Disease Interception Approach To Prevent The Clinical Onset Of Type 1 Diabetes
2/12/2015
-
Janssen Research & Development Sets A Course To Intercept Type 1 Diabetes Together With JDRF
2/12/2015
-
Janssen Research & Development Release: IMBRUVICA (ibrutinib) Shows Sustained Progression-Free Survival In Patients With High-Risk Chronic Lymphocytic Leukemia With Genetic Mutation
12/9/2014
-
Janssen Research & Development Release: IMBRUVICA (ibrutinib) Long-term Follow-up Data In Patients Living With Relapsed/Refractory Mantle Cell Lymphoma Show Almost Half Alive At Two Years
12/9/2014
-
Janssen Research & Development Submits New Drug Application For YONDELIS (trabectedin) To U.S. FDA For The Treatment Of Patients With Advanced Soft Tissue Sarcoma
11/25/2014
-
Janssen Research & Development To Demonstrate Breadth Of Oncology Portfolio With 42 Clinical Data Presentations At The 2014 American Society of Hematology Annual Meeting
11/6/2014
-
Janssen Research & Development Collaborates For Continued Evaluation Of Multidrug-Resistant Tuberculosis Treatment Regimens With SIRTURO® (bedaquiline)
11/6/2014
-
Janssen Research & Development Release: IMBRUVICA® (ibrutinib) Supplemental New Drug Application Submitted To The U.S. FDA For Waldenstrom's Macroglobulinemia
10/20/2014
-
Bristol-Myers Squibb Company, Pharmacyclics, Inc., And Janssen Research & Development Announce Clinical Collaboration To Evaluate OPDIVO® (Nivolumab) And IMBRUVICA®(Ibrutinib) In Non-Hodgkin Lymphoma
10/13/2014
-
Janssen Research & Development Demonstrates Continued Commitment To Combating Hepatitis C In European Patients With Data Presented At Viral Hepatitis Congress
10/10/2014
-
Janssen Research & Development Release: ZYTIGA® Plus Prednisone Demonstrates Statistically Significant Overall Survival After 49-Month Follow-Up Analysis In Chemotherapy-Naive Men With Metastatic Castration-Resistant Prostate Cancer
9/29/2014
-
Janssen Research & Development Expands EXPLORER Global Cardiovascular Research Program To Evaluate The Role Of XARELTO® In Addressing Critical Medical Needs
8/29/2014
-
Janssen Research & Development Release: Data on XARELTO® At ESC Congress 2014 Hot Line Session Premieres First Prospective Study Of A Factor Xa Inhibitor In Elective Cardioversion
8/25/2014
-
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Gains $20 Million Through Deal With Janssen Research & Development
8/22/2014
-
Janssen Research & Development Launches Online Healthy Minds Video Series
8/5/2014
-
Janssen Research & Development Release: New Long-Term Data Show INVOKANA® (canagliflozin) Lowers Blood Glucose In Older Patients With Type 2 Diabetes Inadequately Controlled On Other Therapies
6/17/2014
-
GlaxoSmithKline's ViiV Healthcare Joins Johnson & Johnson's Janssen Research & Development To Develop Single-Pill HIV Drug
6/12/2014
-
Janssen Research & Development To Present Latest Data For Type 2 Diabetes Treatment INVOKANA® (canagliflozin) At American Diabetes Association 74th Scientific Sessions®
6/10/2014